Tracer library / [68Ga]Ga-PSMA-I&T
[68Ga]Ga-PSMA-I&T
Also written as [68Ga]Ga-PSMA-I&T
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 5
What it is
- Compound class
- PSMA-targeted urea-based small molecule ligand (EuK-Sub-kff-DOTAGA)
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 33679149
- Clinical application
- PET/CT imaging of biochemically recurrent prostate cancer PMID 26975008
- Theranostic pair
- [177Lu]Lu-PSMA-I&T
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| GAIA Elysia-Raytest | vendor cassette | SPE | 65% | >95% HPLC | PSMA-I&T ABX | 38424422 2024 Curr Radiopharm A GAIA® synthesis module and a GALLIAD® generator were used. - the results obtained with this buffer were considerably better, with a 65% RCY and a >95% RCP in HPLC. |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | >99% | PSMA I&T (EuK-Sub-kf-(3-iodo-y-), DOTAGA) ABX | 33679149 2021 Turk J Chem the Scintomics GRP synthesizer using cationic purification |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | — | PSMA I&T | 40897948 2025 Mol Imaging Biol Similarly, [68 Ga]Ga-PSMA I&T was also synthesized using the Scintomics system for comparison scans. |
| GAIA Elysia-Raytest | vendor cassette | SPE | 65% | >95% | PSMA-I&T ABX | 38424422 2024 Curr Radiopharm For [68Ga]Ga-PSMA-I&T preparation, the automated sequence described above was used unchanged. - the results obtained with this buffer were considerably better, with a 65% RCY and a >95% RCP in HPLC. |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | SPE | — | >99% | PSMA I&T (EuK-Sub-kf-(3-iodo-y-) DOTAGA) ABX | 33679149 2021 Turk J Chem Original Scintomics radiosynthesis module equipped with cassette for the labelling of PSMA I&T peptide. |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007.2025 · Eur J Nucl Med Mol Imaging · Multicentre
- PSMA PET Evaluation with a Deep Learning Platform Compared with a Standard Image Viewer and Histopathology.2025 · J Nucl Med · Retrospective
- The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.2019 · Ann Nucl Med · Retrospective
- Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.2017 · J Nucl Med · Retrospective
- Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.2017 · Eur J Nucl Med Mol Imaging · Retrospective
- Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.2022 · Eur J Nucl Med Mol Imaging · Clinical study
- The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival.2019 · Ann Nucl Med · Clinical study
- Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T.2018 · Mol Imaging Biol · Clinical study
- 68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.2017 · Nucl Med Mol Imaging · Clinical study
- Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma.2017 · Eur J Nucl Med Mol Imaging · Clinical study
Show all 11 clinical studies
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.2015 · J Nucl Med · Clinical study
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- ABX
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [68Ga]Ga-PSMA-I&T, or handle the enquiry for you.
Get in touchQuality control Derived from the published synthesis
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator-produced per synthesis data (PMID 38424422) -> Ge-68 breakthrough; receptor ligand with a saturable target -> molar activity (rule)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-PSMA-I&T.
Get in touchNotes
Added from reverse module search (stage 6); 5 article(s) with Ga-68. Compound class inferred from precursor name (not stated outright) -- PMID 33679149: 'EuK-Sub-kf-(3-iodo-y-), DOTAGA'.